Search Results

The country is also playing a key role in global clinical research, approving an average of 100 global clinical trials annually. (Representational image: Pixabay)
MedBound Blog

DCGI: India Now Supplies Drugs, Vaccines, and Medical Devices to Over 200 Nations

Vaishnavi Vilas Dalvi, B. Pharm
2 min read
DCGI Highlights India's Contributions to Global Healthcare; Pharmaceutical Industry's Future Directions
Medicine capsules global health with geometric pattern digital remix
Pharmacy

Glenmark Brings Advanced Blood Cancer Treatment to India with DCGI-Approved Brukinsa

M Subha Maheswari, MSc Biotechnology
2 min read
Glenmark Launches DCGI-Approved Brukinsa to Transform Blood Cancer Treatment in India
DCGI recalls 49 drugs from the market after quality lapses; spurious products traced to unauthorized sources. (Representational Image-Wikimedia Commons)
Medicine

DCGI Orders Recall of 49 drugs After Quality Issues, Action Against Spurious Drug Makers Initiated

Ankur Deka
2 min read
Batch-specific recall of painkillers, antifungals, and diabetes drugs; spurious products traced to unauthorized manufacturers
New code would help reduce increasing complexities in drug manufacturing, distribution etc. (PIXABAY)
Pharmacy

"DCGI" Issues Enhanced Code for Drug Inspectors : For Enhancing Transparency and Compliance in 2024

MBT Desk
3 min read
New code may have some implications for the pharmaceutical companies but would benefit consumers
The DCGI stated the anti-cancer drug that is mostly used to treat patients with gBRCA mutation, and those with advanced ovarian cancer & breast cancer is said to have adverse effects. (Representational image: Wikimedia Commons)
MedBound Blog

DCGI Orders Withdrawal of Anti-Cancer Drug Olaparib

MBT Desk
2 min read
The Drug Controller General of India has asked state and Union Territory regulators to withdraw AstraZeneca's cancer drug Olaparib
A person holding a measuring tape around her waist.
Medicine

Retatrutide: The Next-Generation Weight-Loss Drug Outperforming Ozempic and Zepbound

MBT Desk
3 min read
Experimental triple-hormone therapy achieved up to 24.2% weight loss in Phase 2 trials, but it remains under investigation and is not yet FDA approved.
Read More
logo
Medbound Times
www.medboundtimes.com